(RTTNews) - OS Therapies, Inc. (OSTX) has received a Notice of Allowance from the U.S. Patent & Trademark Office or USPTO for a patent covering the manufacturing methods required for the OST-HER2 commercial product.
The patent includes a Patent Term Adjustment of 572 days, extending market exclusivity for OST-HER2 in the U.S. until 2040.
OST-HER2 has been successfully studied in a Phase 2b clinical trial in the prevention of recurrent, resected, lung metastatic osteosarcoma. The company is preparing to submit a Biologics Licensing Application to the FDA for OST-HER2, with hopes of securing accelerated approval in 2025.
OST-HER2 has already received multiple FDA designations, including fast track and orphan drug status in 2021, and similar recognition from the European Medicines Agency or EMA.
OST-HER2 has also shown promising preclinical results in treating breast cancer and other solid tumors, presenting substantial market potential.
CEO John Doe emphasized that this patent milestone strengthens OST-HER2's development and underscores its future in treating osteosarcoma and breast cancer.
OSTX closed Wednesday's (Feb.19 2025) trading at $1.86 down by 5.58%. In premarket trading Thursday the stock is up by 7.53% at $2.00.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
